BPTH (Bio-Path Holdings) Buyback Yield %: 0.00 (As of Jul. 01, 2026)


What is Bio-Path Holdings Buyback Yield %?

Bio-Path Holdings BPTH +45.96% Buyback Yield % is 0.00 as of Jul. 01, 2026. The stock has 1 warning sign investors should review. Among 745 Biotechnology companies, Bio-Path Holdings ranks worse than 134228.05% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Bio-Path Holdings's current buyback yield was 0.00%.

Bio-Path Holdings Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Bio-Path Holdings's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Path Holdings Buyback Yield % Chart

Bio-Path Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26.99 -58.71 -14.43 -29.30 -159.86

Bio-Path Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -159.86 -745.43 -246.11 -655.97 0.00

BPTH vs VBIO, HEPA, AXIM: Buyback Yield % Comparison

For the Biotechnology subindustry, Bio-Path Holdings's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Path Holdings Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Bio-Path Holdings's Buyback Yield % falls into.


Bio-Path Holdings Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Bio-Path Holdings's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 10.696) / 6.69088
=-159.86%

Bio-Path Holdings's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 0.56052
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
Bio-Path Holdings (BPTH) has a Buyback Yield % of 0.00 as of Jul. 01, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Bio-Path Holdings and its competitors. According to the industry distribution chart, Bio-Path Holdings ranks #999999 out of 745 companies in the Biotechnology industry.
Is Bio-Path Holdings' Buyback Yield % too high?
Bio-Path Holdings' current Buyback Yield % is 0.00. Based on the distribution chart, Bio-Path Holdings ranks #999999 out of 745 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Bio-Path Holdings' Buyback Yield % compare to VBIO and HEPA?
According to the Biotechnology industry distribution chart, Bio-Path Holdings ranks #999999 out of 745 companies for Buyback Yield %. This places Bio-Path Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Bio-Path Holdings and its competitors. Bio-Path Holdings's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Path Holdings stock overvalued right now?
Bio-Path Holdings (BPTH) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Bio-Path Holdings (BPTH), the current Buyback Yield % is 0.00 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bio-Path Holdings Business Description

Address No. 2407, 625 Stanwix Street, Pittsburgh, PA, USA, 15222
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.